Bayesian designs for phase I-II clinical trials / Ying Yuan, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Hoang Q. Nguyen,The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Peter F. Thall The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

Why conduct phase I-II trials?
The phase I-II paradigm
Establishing priors
Efficacy-toxicity trade-off-based designs
Designs with late-onset outcomes
Utility-based designs
Personalized dose finding
Combination trials
Optimizing molecularly targeted agents
Optimizing doses in two cycles
Optimizing dose and schedule
Dealing with dropouts
Optimizing intra-arterial tPA
Optimizing sedative dose in preterm infants.